The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Including Contineum’s IPO, biotechs have now raised about $1.43 billion in new stock offerings this year, nearly quadrupling last year’s total by this point.

    Updated April 5, 2024
  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip

    Neumora’s schizophrenia drug hit with clinical hold

    Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.

  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche reports survival data for new dual-acting lymphoma drug

    The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip

    Ultragenyx says Angelman therapy is working, but safety questions remain

    Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.

  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    European regulator concludes no suicide link to obesity drugs

    The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip

    Roche, Adaptimmune part ways on cell therapy research

    The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Vertex’s proposed buyout of Alpine Immune Sciences is the largest biotech acquisition to be announced so far this year.

    Updated April 10, 2024
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US sues Regeneron, alleging false price reporting on Eylea

    The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex to buy kidney disease drugmaker Alpine for $4.9B

    A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.

    Updated April 11, 2024
  • NK Cell (Natural Killer Cell) Attacking a Cancer Cell
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Emerging biotech

    Century buys a startup, raises funding in cell therapy expansion

    The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.

  • A pregnant person is checked with a stethoscope in a doctor's office.
    Image attribution tooltip
    PeopleImages via Getty Images
    Image attribution tooltip

    J&J, Rallybio partner on drug development for rare fetal condition

    The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis pauses enrollment in some Kisqali trials to fix manufacturing

    The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    RSV vaccines

    Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59

    The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old.

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip
    Emerging biotech

    PureTech launches Seaport, hoping to create Karuna 2.0

    The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.

  • Two people in white coats work at a laboratory bench.
    Image attribution tooltip
    Adene Sanchez via Getty Images
    Image attribution tooltip

    Private biotech funding rises as venture firms deploy cash

    Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Dive.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Trial shows Wegovy can ease heart failure symptoms

    The results were the second time Novo has shown its weight loss treatment can help with the condition, and may help it secure broader use of the drug.

  • Business Woman pushing large stone uphill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Women want to participate in clinical trials. Lack of flexibility is still a problem.

    Underrepresentation of women in clinical trials affects the resulting drugs that become available later. Even small changes could boost participation.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use

    The FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s Carvykti, but gave the rival treatments different labels.

    Updated April 8, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    Boehringer Ingelheim to lay off staff amid biosimilar challenges

    The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx to pull ALS drug from market in rare move

    In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    Emerging biotech

    Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs

    The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.

  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire Shockwave Medical for $13.1B

    The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.

    Updated April 5, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck puts KRAS cancer drug competitor to the test

    A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

  • An illustration of antibiotic-resistant bacteria, including Staphylococcus aureus
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    FDA approves new antibiotic for several hard-to-treat infections

    Swiss pharma Basilea has won clearance for Zevtera after a long development journey, but is still searching for a commercial partner in the U.S.

    FDA
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

    The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.